GlaxoSmithKline PLC and Genmab A/S will end the development of an intravenous form of a drug intended to treat autoimmune diseases like lupus and multiple sclerosis, and focus on an injectable version.
The companies said an injectable version of Arzerra (ofatumumab) should be more convenient for patients and have fewer side effects. The drug can also be used to treat rheumatoid arthritis...Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1397